← All trials
NCT06364631
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 12, 2024
- Primary completion
- May 5, 2032
- Completion date
- May 5, 2032
- First posted
- Apr 15, 2024
- Last posted
- Apr 19, 2024
- Enrollment
- 1250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut Gustave RoussyLead sponsor
- Institut Gustave RoussyOfficial
- University of RennesCollaborator
- University of MilanCollaborator
- National Cancer Institute, FranceCollaborator
- Universidad Complutense de MadridCollaborator
- Netherlands Cancer InstituteCollaborator
- University of Duisburg-EssenCollaborator
- European CommissionCollaborator
- University of LondonCollaborator
- Medical University of ViennaCollaborator
- Spanish National Health SystemCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.